Supportive Care in Acute Myeloid Leukemia



Ruben A. Mesa, MD, FACP, moderates this discussion with Rafael Bejar, MD, PhD; Elias Jabbour, MD; and Rami Komrokji, MD. These experts in hematology and oncology discuss the pathways involved in leukemic transformation, risk-adjusted approaches to treatment, and supportive care in acute myeloid leukemia.

In this segment, Ruben A. Mesa, MD, FACP; Rami Komrokji, MD; and Elias Jabbour, MD, highlight essential supportive care strategies in acute myeloid leukemia (AML) treatment.

Patients with acute myeloid leukemia (AML) must be able to endure their therapy, states Ruben A. Mesa, MD, FACP. Patient outcomes are compromised if they are unable to tolerate what becomes a complicated course of treatment, says Mesa, making the application of supportive care practices highly important in the management of AML.

Complications of leukostasis, for example, may be encountered during the treatment of the AML subtype, acute promyelocytic leukemia (APL), precipitating the need for supportive care, such as leukapheresis, to control the white blood cell counts.

Episodes of bleeding may occur in patients suffering from disseminated intravascular coagulopathy (DIC) as well as those not in DIC, states Rami Komrokji, MD, citing the need for blood transfusions.

Patients may develop mucositis, making them vulnerable to infectious processes and febrile neutropenia. This makes infection prophylaxis key, notes Komrokji, whose institution utilizes triple coverage with antibacterial, antifungal, and antiviral agents. Empirically, practitioners should be very aggressive with anti-infective therapies, adds Elias Jabbour, MD, emphasizing the importance of initiating antibiotics before obtaining a positive culture. Many of the anti-infective agents may also cause QT prolongation, says Jabbour, which must be carefully monitored.

Related Videos
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
Solutions to Prevent Climate Change-Related Illness, with Janelle Bludhorn, PA-C
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
What Should the American Academy of Physician Associates Focus on in 2025?
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
© 2024 MJH Life Sciences

All rights reserved.